Posted on 03/08/2010 in Scientific Life Technologies has experienced year-on-year growth in the second quarter of 2010, according to its latest fiscal report.
The science group, which operates the Invitrogen and Applied Biosystems brands, saw revenue increase by eight per cent to $906 million (568.5 million pounds), compared to $839 million in Q2 2009.
Businesses which experienced growth during the quarter included its molecular biology, cell and genetic systems divisions, while sales through e-commerce channels also increased.
Gregory Lucier, chairman and chief executive officer of Life Technologies, said the results were indicative of the firm's "sustained organic growth" during the last three months.
He added: "Our continued focus on strong execution enabled us to once again deliver value to our shareholders through record levels of operating margin and strong year-over-year earnings per share growth."
Earlier this year, Life Technolgies agreed a deal to provide Invitrogen primary and stem cell technology for use in amyotrophic lateral sclerosis conducted by the University of California, San Diego and the Salk Institute for Biological Studies. Other news stories from 03/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
